Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

In this CME article, learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia.

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

An expert gives us a preview of the clinical pearls clinicians can expect from his presentations at this year’s APA Annual Meeting.

In this CME article, discuss and describe the epidemiology, assessment, and evidence-based treatment of insomnia in older adults.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

OABD is a significant concern among older adults, characterized by unique presentations and comorbidities. Here's what you need to know.

Although psychiatric disorders are common among older adults, many of these individuals do not get the treatment they need. The Psychiatric Times Special Report on Geriatric Psychiatry discusses how we can improve outcomes for this patient population.

In this CME article, learn how to evaluate older adults who present with significant appetite and weight changes for the presence of an eating disorder.

What treatments are available for those with older age bipolar disorder?

Between 1980 and 1998, the relative frequency of late-onset bipolar disorder increased from 1% to 11%. How can you best assess for this condition?

What is the first thing you share with your patient when you are about to prescribe a new medication?

In this CME, evaluate the treatment options for depression among older adults.

In this CME article, learn about the best ways to assess depression in the geriatric population.

COVID-19 has prompted an unprecedented shift toward virtual psychiatric health care—but how do patients and providers really feel about it?

Secondary causes for psychosis are more common in older adults (65 years or older) than in younger patients. Here are 6 possible culprits.

Most psychotic disorders appear in adolescents or young adults, but some also occur during later life. Here's how to recognize and treat them.